Sandoz Sanguine On Market Opportunity Despite Biosimilar Neulasta Setback
Executive Summary
Questions from European regulators around Sandoz's market application for biosimilar pegfilgrastim have prompted the company to withdraw the drug's filing – a delay which could allow competitor biosimilar developers to launch ahead of the Novartis-owned company.
You may also be interested in...
Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.
Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.
Biosimilar Trade Secrets: Coherus Hiring Of Amgen Exec Leads To Theft Suit
Three months before user fee date for Coherus' Neulasta (pegfilgrastim) biosimilar, Amgen claims company stole confidential information including pricing and contracting strategies.